<DOC>
	<DOCNO>NCT01522170</DOCNO>
	<brief_summary>There grow limited information long term clinical status aHUS patient previously receive continue receive treatment eculizumab . This study design collect clinical data provide insight long-term outcome patient aHUS .</brief_summary>
	<brief_title>aHUS Observational Long Term Follow-Up</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>aHUS patient participate one aHUSeculizumab clinical study . aHUS patient legal representative able willing give write informed consent study information collect retained database .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Atypical Hemolytic Uremic Syndrome</keyword>
	<keyword>aHUS</keyword>
	<keyword>Eculizumab</keyword>
</DOC>